Paris, January 11, 2010 – Cellectis S.A. (Alternext: ALCLS), the French genome engineering specialist, has announced that it will take part in BioPartnering North AmericaTM 2010 in Vancouver, Canada, on January 24-26. Over the course of the 3-day business convention, Cellectis’ Business Development Director Luc Mathis will represent the company and present its portfolio of products and intellectual property to leading pharmaceutical and biotech companies.
About Cellectis S.A.
Cellectis SA is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in in vivo genome surgery addressing the therapeutic, food processing, bioproduction and research sectors. Worldwide, Cellectis has entered into more than 50 agreements with major players in the pharmaceutical, biotechnology and agrobiotechnology industries, and has over 20 collaborations with academic research groups. To date, Cellectis has raised over €70 million in both equity operations and public financing and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For further information about Cellectis, visit our website: www.cellectis.com
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with its IPO and on which the French Autorité des marchés financiers (“AMF”) granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
